US Edition
Published • loading... • Updated
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
- Eilean Therapeutics LLC presented data on its pan-EGFR inhibitor, ZE77-0273, highlighting its broad activity against resistance mutations in EGFR-mutant non-small cell lung cancer .
- ZE77-0273 shows a high selectivity index versus wild-type EGFR and has a wide therapeutic window characterized by excellent safety and tolerability.
- Eilean Therapeutics specializes in developing first-in-class and best-in-class small molecule inhibitors targeting escape mutations in cancer, utilizing a proprietary hybrid AI/ML drug design platform to optimize drug discovery and enhance therapies for therapy-resistant lung cancer.
Insights by Ground AI
46 Articles
46 Articles
keenesentinel.com+45 Reposted by 45 other sources
EiIean Therapeutics Presents Novel Wild-Type Sparing, Reversible Pan-EGFR Inhibitor (ZE77-0273) with Broad Activity Against Resistance Mutations in EGFR-Mutant NSCLC at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
DOVER, Del., Oct. 13, 2025 /PRNewswire/ -- Eilean Therapeutics LLC, a biopharmaceutical company dedicated to discovering and developing best-in-class and first-in-class small molecule inhibitors targeting escape mutations in hematologic malignancies and solid tumors, today announced the presentation of data for…
Coverage Details
Total News Sources46
Leaning Left3Leaning Right5Center12Last UpdatedBias Distribution60% Center
Bias Distribution
- 60% of the sources are Center
60% Center
15%
C 60%
R 25%
Factuality
To view factuality data please Upgrade to Premium
